
Page#1
ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
Year Ended December 31,
(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) 2018 2017 2016
Revenue $ 5,825 $ 5,307 $ 4,888
Costs and expenses:
Cost of sales(a) 1,911 1,775 1,666
Selling, general and administrative expenses(a) 1,484 1,334 1,364
Research and development expenses(a) 432 382 376
Amortization of intangible assets 117 91 85
Restructuring charges and certain acquisition-related costs 68 19 5
Interest expense, net of capitalized interest 206 175 166
Other (income)/deductions––net (83) 6 (2)
Income before provision for taxes on income 1,690 1,525 1,228
Provision for taxes on income 266 663 409
Net income before allocation to noncontrolling interests 1,424 862 819
  Less: Net loss attributable to noncontrolling interests (4) (2) (2)
Net income attributable to Zoetis $ 1,428 $ 864 $ 821
Earnings per share attributable to Zoetis Inc. stockholders:
 Basic $ 2.96 $ 1.76 $ 1.66
 Diluted $ 2.93 $ 1.75 $ 1.65
Weighted-average common shares outstanding:
 Basic 483.063 489.918 495.715
 Diluted 486.898 493.161 498.225
Dividends declared per common share $ 0.542 $ 0.441 $ 0.390
(a) Exclusive of amortization of intangible assets, except as disclosed in Note 3. Significant Accounting Policies—Amortization of Intangible Assets, Depreciation and 
Certain Long-Lived Assets. 
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
63 |
Page#2
ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS 
December 31, December 31,
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) 2018 2017
Assets
Cash and cash equivalents(a) $ 1,602 $ 1,564
Short-term investments 99 —
Accounts receivable, less allowance for doubtful accounts of $24 in 2018 and $25 in 2017 1,036 998
Inventories 1,391 1,427
Other current assets 271 228
Total current assets 4,399 4,217
Property, plant and equipment, less accumulated depreciation of $1,599 in 2018 and $1,471 in 2017 1,658 1,435
Goodwill 2,519 1,510
Identifiable intangible assets, less accumulated amortization 2,046 1,269
Noncurrent deferred tax assets 61 80
Other noncurrent assets 94 75
Total assets $ 10,777 $ 8,586
Liabilities and Equity
Short-term borrowings $ 9 $ —
Accounts payable 313 261
Dividends payable 79 61
Accrued expenses 487 432
Accrued compensation and related items 266 236
Income taxes payable 35 60
Other current liabilities 34 44
Total current liabilities 1,223 1,094
Long-term debt, net of discount and issuance costs 6,443 4,953
Noncurrent deferred tax liabilities 474 380
Other taxes payable 265 172
Other noncurrent liabilities 187 201
Total liabilities 8,592 6,800
Commitments and contingencies (Note 17)
Stockholders' equity:
Preferred stock, $0.01 par value; 1,000,000,000 authorized, none issued — —
Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued;  
479,562,326 and 486,130,461 shares outstanding at December 31, 2018 and 2017, respectively 5 5
Treasury stock, at cost, 22,328,917 and 15,760,782 shares of common stock at December 31, 2018 and 2017,
respectively (1,487) (852)
Additional paid-in capital 1,026 1,013
Retained earnings 3,270 2,109
Accumulated other comprehensive loss (629) (505)
Total Zoetis Inc. equity 2,185 1,770
Equity attributable to noncontrolling interests — 16
Total equity 2,185 1,786
Total liabilities and equity $ 10,777 $ 8,586
(a) As of December 31, 2018, and December 31, 2017, includes $5 million and $6 million, respectively, of restricted cash.
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
65 |
Page#3
  ZOETIS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(MILLIONS OF DOLLARS) 2018 2017 2016
Operating Activities
Net income before allocation to noncontrolling interests $ 1,424 $ 862 $ 819
Adjustments to reconcile net income before noncontrolling interests to net cash
provided by operating activities:
Depreciation and amortization expense 308 242 240
Share-based compensation expense 53 44 37
Asset write-offs and asset impairments 4 3 5
Net (gain)/loss on sales of assets (42) 11 (26)
Provision for losses on inventory 54 54 105
Deferred taxes(a) (112) 127 (55)
Employee benefit plan contribution from Pfizer Inc. 3 3 3
Other non-cash adjustments (14) 10 19
Other changes in assets and liabilities, net of acquisitions and divestitures
Accounts receivable (67) (50) 15
Inventories 61 19 (101)
Other assets (42) (16) (50)
Accounts payable 37 (10) (28)
Other liabilities 56 (38) (290)
Other tax accounts, net 67 85 20
Net cash provided by operating activities 1,790 1,346 713
Investing Activities
Capital expenditures (338) (224) (216)
Acquisition of Abaxis, net of cash acquired (1,884) — —
Other acquisitions (114) (82) (88)
Net proceeds from sales of assets 56 37 90
Proceeds from maturities and redemptions of investments 28 — —
Other investing activities (7) (1) —
Net cash used in investing activities (2,259) (270) (214)
Financing Activities
Increase/(decrease) in short-term borrowings, net 8 — (5)
Principal payments on long-term debt — (750) (400)
Proceeds from issuance of long-term debt—senior notes, net of discount and fees 1,485 1,231 —
Payment of contingent consideration related to previously acquired assets (12) (7) (32)
Share-based compensation-related proceeds, net of taxes paid on withholding shares and excess tax benefits 19 24 25
Purchases of treasury stock (698) (500) (300)
Cash dividends paid (243) (206) (188)
Acquisition of a noncontrolling interest (26) (43) —
Payment of debt issuance costs — — (3)
Net cash provided by/(used in) financing activities 533 (251) (903)
Effect of exchange-rate changes on cash and cash equivalents (26) 12 (23)
Net increase/(decrease) in cash and cash equivalents 38 837 (427)
Cash and cash equivalents at beginning of period 1,564 727 1,154
Cash and cash equivalents at end of period $ 1,602 $ 1,564 $ 727
See Notes to Consolidated Financial Statements, which are an integral part of these statements.
67 |